Search Results for "Lundback Pharma"
Original Source: Lundbeck
Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D efforts to central nervous system (CNS) disorders.
Matching Channels
The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...
Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...
OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar t...
Lyxumia® is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is re...
Devices - medical, biotech, pharma
A medical device is a product which is used for medical purposes in patients, in diagnosis, therapy or surgery. Medical devices act by physical, mechanical, thermal, physico-chemical or chemic...
Matching News
Pharma 3.0 Pulls Companies into the Digital Future
Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0. Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...
Big pharma companies BMS and Merck are pharma partnering on Daclatasvir
Big pharma company, Bristol-Myers Squibb, is pharma partnering with another big pharma company, Merck, to develop Daclatasvir to treat Hepatitis C. The big pharma companies will work on the hepatitis...
Merck enter pharma partnering pact with Ra Pharma for cyclomimetics
Ra Pharmaceuticals has entered into a pharma partnering deal with Merck, a top 50 big pharma corporation, focused on the development of Cyclomimetics, a new class of compounds that have the diversity...
Verona Pharma plc: Analyst Presentation on the Company Website
LONDON, April 10, 2013 /PRNewswire/ -- Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology co...
Big Pharma performance continues to receive muted reviews from various analysts and industry commentators. Pharma Reform starts with an analysis of drug approvals in 2012 by FDA. It is TRUE that 35 dr...
Bad Pharma by Dr Ben Goldacre; the mechanics of a mediocre argument
Nick Broughton discusses Dr Ben Goldacre’s latest book, Bad Pharma, and comments on why he believes it was a wasted opportunity for the pharma industry. If you are working in pharma and are not awa...
Pharma IQ’s Top Pharma Bloggers of 2013
Pharma IQ put out it’s list of the Top Pharma Bloggers for 2013. These lists tend to be subjective and always leave off many great sites. But, these can be a good way to discover a blog you have...
Catalent and UMN Pharma Announce Collaboration for Biosimilar Development and Production in Japan
Catalent Pharma Solutions and UMN Pharma Inc. today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent’s proprietary GPEx ® techno...
Matching PubMed Articles
Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...
Is pharma running out of brainy ideas?
